Arcutis Biotherapeutics Inc. (ARQT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arcutis Biotherapeutics I... (ARQT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.27

-0.36 (-2.64%)

At close: Jan 14, 2025, 3:59 PM

13.21

-0.43%

After-hours Jan 14, 2025, 07:40 PM EST

undefined% (undefined)

Bid	11.52
Market Cap	1.55B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.67
PE Ratio (ttm)	-7.95
Forward PE	n/a
Analyst	Buy

Ask	15.38
Volume	1,553,441
Avg. Volume (20D)	2,118,596
Open	13.79
Previous Close	13.63
Day's Range	13.10 - 14.12
52-Week Range	3.11 - 16.20
Beta	undefined

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 31, 2020

Employees 296

Stock Exchange NASDAQ

Ticker Symbol ARQT

Website https://www.arcutis.com

Analyst Forecast

According to 5 analyst ratings, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 43.18% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arcutis Biotherapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $54.67M, reflecting a 304.18% YoY growth and earnings per share of -0.29, making a -59.72% decrease YoY.

Why Price Moved

1 week ago · Source

+7.14%

Arcutis Biotherapeutics shares are trading higher ... Unlock content with Pro Subscription

8 months ago · Source

+13.65%

Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

News

1 week ago · zacks.com

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

2 weeks ago · zacks.com

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

1 month ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT's 50-day simple moving average broke out a...

1 month ago · zacks.com

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

1 month ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 50-day moving average, suggest...

1 month ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 200-day moving average, an...

1 month ago · zacks.com

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Arcutis Biotherapeutics (ARQT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

1 month ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT broke through the 20-day moving average, w...

2 months ago · seekingalpha.com

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% qu...

2 months ago · zacks.com

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

The consensus price target hints at a 70.3% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago · seekingalpha.com

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Wat...

2 months ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.73 per share a year ago.

2 months ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.